Portfolio company
Artbio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops alpha radioligand therapies and manufacturing infrastructure to treat patients with prostate cancer and other solid tumours.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Actithera Group
This company develops radioligand therapies to treat cancer patients by delivering radiation directly to solid tumours while sparing healthy tissue.
Actithera
This biotechnology company develops targeted radioligand therapies to treat cancer patients by delivering radioactive isotopes directly to solid tumours.
Alpha-9 Oncology
The company develops radiopharmaceutical therapies for patients with solid and haematologic malignancies.
Aktis Oncology
This biotechnology company develops alpha-emitting radiopharmaceuticals to treat patients with solid tumor cancers.
Alpha-9 Theranostics
This clinical-stage biotechnology company develops targeted radiopharmaceuticals to treat cancer patients by delivering radiation directly to tumours while sparing healthy tissue.
Rayze Bio
RayzeBio develops targeted radiopharmaceutical therapies using alpha-emitting isotopes to treat patients with solid tumours and other cancers.
Full-Life Technologies
This company develops radiopharmaceuticals and radionuclide drug conjugates to treat cancer patients through targeted alpha therapy.
Oncoinvent ASA
This deep-tech company develops injectable alpha radiation therapies for patients with cancers located in the peritoneal cavity.